H.C. Wainwright lowered the firm’s price target on Personalis (PSNL) to $8 from $11 and keeps a Buy rating on the shares.The firm believes the company’s revenue from client Natera (NTRA), that has been a lion share of its enterprise sales, may not be meaningful in 2025 as the relationship continues to wind down. It expects meaningful contribution from the expanded collaboration agreement with Personalis’ partner, Tempus, to be realized in 2026 and beyond.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis publishes results from TRACERx lung cancer study in Nature Medicine
- Personalis price target raised to $9 from $7 at Lake Street
- Personalis reports preliminary Q4 revenue $16.8M, consensus $15.5M
- Personalis raises FY24 revenue view to $84.6M from $83M-$84M
- Personalis up 3% at $6.15 after Q4 pre-announcement, FY24 guidance increase